Jeremy R Johnson

Summary

Country: UK

Publications

  1. doi An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics
    Jeremy R Johnson
    Shropshire and Mid Wales Hospice, Shrewsbury, Shropshire, United Kingdom
    J Pain Symptom Manage 46:207-18. 2013
  2. doi Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain
    Jeremy R Johnson
    Severn Hospice, Shrewsbury, Shropshire, United Kingdom
    J Pain Symptom Manage 39:167-79. 2010

Detail Information

Publications2

  1. doi An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics
    Jeremy R Johnson
    Shropshire and Mid Wales Hospice, Shrewsbury, Shropshire, United Kingdom
    J Pain Symptom Manage 46:207-18. 2013
    ..The Δ9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (U.S. Adopted Name, nabiximols; Sativex(®)) is a novel cannabinoid formulation currently undergoing investigation as an adjuvant therapy for this treatment group...
  2. doi Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain
    Jeremy R Johnson
    Severn Hospice, Shrewsbury, Shropshire, United Kingdom
    J Pain Symptom Manage 39:167-79. 2010
    ..0). Most drug-related adverse events were mild/moderate in severity. This study shows that THC:CBD extract is efficacious for relief of pain in patients with advanced cancer pain not fully relieved by strong opioids...